Description

Deruxtecan analog 2 (example 9 P3) is a Deruxtecan (HY-13631E) analog. Deruxtecan analog 2 is a agent-linker conjugate composed of Camptothecin (HY-16560) and a linker. Camptothecin (CPT) is a Topo I inhibitor with antineoplastic activity against colorectal, breast, lung and ovarian cancers. Deruxtecan analog 2 can be used for the preparation anti-FGFR2 ADC[1].–20°C (Powder, protect from light, stored under nitrogen)-Applications-Cancer-programmed cell death-Formula-C29H30FN5O7-Citation–References-[1]Daly Christopher, et, al. Anti-FGFR2 antibodies and antibody-drug conjugates methods of use thereof. Patent WO2022087243. -CASNumber-1599440-10-4-MolecularWeight-579.58-Compound Purity-99.48-SMILES-O=C(N[C@H]1CCC2=C3C1=C(CN4C(C(COC([C@@]5(CC)O)=O)=C5C=C46)=O)C6=NC3=CC(F)=C2C)COCNC(CN)=O-Research_Area-Cancer-Solubility-DMSO : 100 mg/mL (ultrasonic)-Target-Drug-Linker Conjugates for ADC-Isoform–Pathway-Antibody-drug Conjugate/ADC Related-MCE Product type-ADC Related